Mr Carl Gibson, chief executive of Complementary Medicines Australia (CMA) has welcomed results from a new study which shows equivalent benefits of taking glucosamine and chondroitin for osteoarthritis (OA) of the knee as taking the COX-2 inhibitor celecoxib (Celebrex).

Read the media release here